464 related articles for article (PubMed ID: 26407619)
1. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
3. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
[TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation.
Reveles KR; Backo JL; Corvino FA; Zivkovic M; Broderick KC
Pharmacotherapy; 2017 Dec; 37(12):1489-1497. PubMed ID: 29044643
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States.
Stranges PM; Hutton DW; Collins CD
Value Health; 2013; 16(2):297-304. PubMed ID: 23538181
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
Burton HE; Mitchell SA; Watt M
Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
[TBL] [Abstract][Full Text] [Related]
9. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
Cornely OA; Watt M; McCrea C; Goldenberg SD; De Nigris E
J Antimicrob Chemother; 2018 Sep; 73(9):2529-2539. PubMed ID: 29800295
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
[TBL] [Abstract][Full Text] [Related]
11. Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C
Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
Watt M; McCrea C; Johal S; Posnett J; Nazir J
Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Okumura H; Ueyama M; Shoji S; English M
J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
Nelson RL; Suda KJ; Evans CT
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
[TBL] [Abstract][Full Text] [Related]
16. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
[TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin for the treatment of Clostridium difficile infections.
Whitman CB; Czosnowski QA
Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
[TBL] [Abstract][Full Text] [Related]
18. Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
Morrow T
Manag Care; 2011 Jul; 20(7):49-50. PubMed ID: 21848202
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
Ford DC; Schroeder MC; Ince D; Ernst EJ
Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]